Clinical Trial Update: A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of Bacterial Conjunctivitis. [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated the safety and effectiveness of 0.6% ISV-403 for acute bacterial conjunctivitis. The study completed and results were posted in 2009.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacterial Conjunctivitis

Drugs mentioned

• ISV-403 (0.6%) (ISV-403)

Snippet

Sponsor: Bausch & Lomb Incorporated | Conditions: Acute Bacterial Conjunctivitis | Phase 3 | Status: COMPLETED | Results posted: 2009-08-13